S
Sonoma Pharmaceuticals, Inc.
SNOACIK 0001367083NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Mar 31
Period
FY 2026
Revenue
$19.53M
Net Income
$-3.17M
Total Assets
$13.96M
Equity
$3.10M
Shares Out
4.79M
Op. Cash Flow
$-3.93M
Business
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection applications. The company sells prescription, over-the-counter, and office-dispense medical devices through direct sales and distribution partnerships across over 55 countries. Products are manufactured at a facility in Mexico and marketed under multiple brand names including Microcyn, Levicyn, Regenacyn, and Lasercyn, with distribution through healthcare practitioners, retailers, and specialty distributors.
Summary from 10-K filed 2026-06-16
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenues | 20 | 14 | 13 | 13 | 13 | |
| Cost of revenues | 12 | 9 | — | — | — | |
| Gross profit | 7 | 5 | 5 | 4 | 4 | |
| Research and development | 2 | 2 | 2 | 207,000 | 125,000 | |
| Selling, general and administrative | 8 | 7 | 8 | 9 | 10 | |
| Total operating expenses | 10 | 9 | 9 | 9 | 10 | |
| Loss from operations | −2 | −4 | −5 | −5 | −6 | |
| Other (expense) income | −958,000 | 803,000 | −330,000 | −614,000 | −394,000 | |
| Loss from operations before income taxes | −3 | −3 | −5 | −5 | −5 | |
| Income tax benefit (expense) | 244,000 | −550,000 | 196,000 | 33,000 | 332,000 | |
| Net loss | −3 | −3 | −5 | −5 | −5 | |
| Net loss per share: basic | −1.89 | −2.79 | −10.63 | −1.52 | −1.92 | |
| Net loss per share: diluted | −1.89 | −2.79 | −10.63 | −1.52 | −1.92 | |
| Weighted-average shares outstanding: basic | 2 | 1 | 455,000 | 3,394 | 2,653 | |
| Weighted-average shares outstanding: diluted | 2 | 1 | 455,000 | 3,394 | 2,653 | |
| Foreign currency translation adjustments | 1 | −2 | 695,000 | 894,000 | 267,000 | |
| Comprehensive loss | −2 | −5 | −4 | −4 | −5 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 5 | 3 | 4 | 7 | |
| Accounts receivable, net | 3 | 2 | 3 | 3 | 2 | |
| Inventories, net | 4 | 3 | 3 | 3 | 3 | |
| Prepaid expenses and other current assets | 3 | 2 | 4 | 4 | 4 | |
| Current portion of deferred consideration, net of discount | 87,000 | 212,000 | 262,000 | — | — | |
| Total current assets | 12 | 13 | 13 | 14 | 16 | |
| Property and equipment, net | 310,000 | 225,000 | 365,000 | 488,000 | 320,000 | |
| Operating lease, right of use assets | 602,000 | 84,000 | 286,000 | 418,000 | 559,000 | |
| Deferred tax asset, net | 884,000 | 589,000 | 1 | 949,000 | 829,000 | |
| Deferred consideration, net of discount, less current portion | 0 | 73,000 | 330,000 | — | — | |
| Other assets | 64,000 | 74,000 | 66,000 | 73,000 | 77,000 | |
| Total assets | 14 | 14 | 15 | 16 | 19 | |
| Accounts payable | 2 | 953,000 | 607,000 | 841,000 | 2 | |
| Accrued expenses and other current liabilities | 2 | 2 | 2 | 2 | 2 | |
| Deferred revenue, current portion | 284,000 | 641,000 | 478,000 | 160,000 | 1 | |
| Short-term debt | 222,000 | 220,000 | 323,000 | 431,000 | — | |
| Operating lease liabilities, current portion | 151,000 | 58,000 | 198,000 | 256,000 | 250,000 | |
| Total current liabilities | 5 | 4 | 4 | 4 | 6 | |
| Deferred revenue, net of current portion | 0 | 17,000 | 87,000 | 140,000 | 182,000 | |
| Withholding tax payable | 6 | 5 | 5 | 4 | 4 | |
| Operating lease liabilities, less current portion | 469,000 | 27,000 | 87,000 | 162,000 | 309,000 | |
| Total liabilities | 11 | 9 | 9 | 8 | 10 | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2026 and 2025, respectively, no shares issued and outstanding at March 31, 2026 and 2025 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 50,000,000 shares authorized at March 31, 2026 and 2025, 1,799,057 and 1,634,265 shares issued and outstanding at March 31, 2026 and 2025, respectively (Note 1) (Note 12) | 0 | 0 | 0 | 5,000 | 2,000 | |
| Additional paid-in capital | 207 | 207 | 203 | 201 | 197 | |
| Accumulated deficit | −201 | −198 | −194 | −190 | −184 | |
| Accumulated other comprehensive loss | −3 | −4 | −3 | −3 | −4 | |
| Total stockholders equity | 3 | 4 | 6 | 8 | 9 | |
| Total liabilities and stockholders equity | 14 | 14 | 15 | 16 | 19 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Depreciation | 139,000 | 138,000 | 176,000 | — | — | |
| Stock-based compensation | 255,000 | 224,000 | 516,000 | 669,000 | 382,000 | |
| Deferred income tax (benefit) expense | −231,000 | 357,000 | −109,000 | −37,000 | −829,000 | |
| Operating lease right-of-use asset | −515,000 | 174,000 | 161,000 | 173,000 | 223,000 | |
| Accounts receivable, net | −122,000 | 434,000 | −230,000 | −4,000 | 2 | |
| Inventories, net | −465,000 | −388,000 | 184,000 | 0 | −100,000 | |
| Prepaid expenses and other current assets | −1 | 1 | 1 | −306,000 | −460,000 | |
| Deferred consideration, net of discount | 237,000 | 194,000 | 222,000 | — | — | |
| Accounts payable | 871,000 | 416,000 | −278,000 | −864,000 | −157,000 | |
| Accrued expenses and other current liabilities | −100,000 | 295,000 | 19,000 | 127,000 | 679,000 | |
| Withholding tax payable | 422,000 | 432,000 | 475,000 | 396,000 | 360,000 | |
| Operating lease liabilities | 515,000 | −174,000 | −161,000 | −173,000 | −222,000 | |
| Deferred revenue | −452,000 | 181,000 | 355,000 | −1 | 900,000 | |
| Net cash used in operating activities | −4 | −88,000 | −2 | −6 | −4 | |
| Purchases of property and equipment | −192,000 | −80,000 | −2,000 | −269,000 | −137,000 | |
| Net cash used in investing activities | −192,000 | −80,000 | −2,000 | −258,000 | −99,000 | |
| Proceeds from issuance of common stock, net of offering expenses | 427,000 | 3 | 2 | 3 | 8 | |
| Proceeds from exercise of employee stock options | 44,000 | 82,000 | 0 | 0 | 216,000 | |
| Payments for fractional shares related to reverse-split | 0 | −1,000 | 0 | — | — | |
| Principal payments on short-term debt | −271,000 | −404,000 | −481,000 | −774,000 | — | |
| Insurance premiums financed | 277,000 | 274,000 | 373,000 | 515,000 | 748,000 | |
| Net cash provided by financing activities | 477,000 | 3 | 2 | 2 | 7 | |
| Effect of exchange rate on cash and cash equivalents | 673,000 | −616,000 | 32,000 | 345,000 | 127,000 | |
| Net (decrease) increase in cash and cash equivalents | −3 | 2 | −692,000 | −4 | 3 | |
| Cash paid for interest | 6,000 | 11,000 | 22,000 | 17,000 | 24,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Sonoma Pharmaceuticals, Inc.'s CIK number?
Sonoma Pharmaceuticals, Inc.'s SEC CIK number is 0001367083 (1367083). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Sonoma Pharmaceuticals, Inc.'s SEC filings?
All of Sonoma Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.